Real-world experience with CPX-351 in high-risk acute myeloid leukemia
- PMID: 37028531
- DOI: 10.1016/j.critrevonc.2023.103984
Real-world experience with CPX-351 in high-risk acute myeloid leukemia
Abstract
CPX-351, a dual-drug liposomal encapsulation of daunorubicin/cytarabine, was approved for newly diagnosed therapy-related acute myeloid leukemia (AML) and AML with myelodysplasia-related changes in adults in 2017 (US; updated to patients aged ≥1 year in 2021) and 2018 (EU/UK) based on improved survival and remission and comparable safety versus 7 + 3 chemotherapy in a randomized trial in older adults. Real-world studies have since evaluated CPX-351 in routine practice across several countries and addressed important data gaps (e.g., use in younger adults, measurable residual disease negativity, outcomes by mutation). This review discusses real-world studies of CPX-351 as AML treatment, with the aim of helping prescribers make informed treatment decisions.
Keywords: AML; CPX-351; Chemotherapy; Cytarabine; Daunorubicin; Measurable residual disease; Real-world.
Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest RML has served as an advisor for Jazz Pharmaceuticals. PM has served as a consultant for and has received speaker honoraria and research funding from Jazz Pharmaceuticals. AJ has no conflicts of interest to disclose.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
